CollPlant files Form 6-K for Q3 2025 results

CollPlant Biotechnologies Ltd. submitted a Form 6-K as a foreign private issuer for November 2025.

Accepted by SEC EDGAR 11/26/2025 - 07:38 AM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. submitted a Form 6-K as a foreign private issuer for November 2025. The company reports that on November 26, 2025 it issued a press release titled “Collplant Biotechnologies Reports 2025 Third Quarter Financial Results and Provides Corporate Update,” which is attached as an exhibit to this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies (CLGN) disclose in this Form 6-K?

CollPlant Biotechnologies filed a Form 6-K stating it issued a press release on November 26, 2025 with its 2025 third quarter financial results and a corporate update, attaching that release as an exhibit.

Does this CollPlant (CLGN) Form 6-K include full Q3 2025 financial results?

The Form 6-K itself mainly notes that CollPlant issued a press release with 2025 third quarter financial results and a corporate update. The detailed numbers and narrative are contained in the attached press release exhibit.

Why is CollPlant Biotechnologies (CLGN) using Form 6-K for this update?

As a foreign private issuer, CollPlant uses Form 6-K to furnish material information like quarterly results and corporate updates to U.S. investors. This filing formally submits its November 26, 2025 press release to the U.S. market.

What is the main subject of CollPlant’s November 26, 2025 press release?

The press release titled “Collplant Biotechnologies Reports 2025 Third Quarter Financial Results and Provides Corporate Update” focuses on CollPlant’s financial performance for the 2025 third quarter and broader corporate developments during that period.

Who signed the CollPlant (CLGN) November 2025 Form 6-K?

The Form 6-K was signed on behalf of CollPlant Biotechnologies Ltd. by Eran Rotem, who is identified as Deputy CEO and Chief Financial Officer, dated November 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On November 26, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “Collplant Biotechnologies Reports 2025 Third Quarter Financial Results and Provides Corporate Update”.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1

Press Release, dated November 26, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.

Date: November 26, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

Source: View Original Filing on SEC EDGAR